Medical Dialogues

Is magnesium deficiency the leading cause of high blood pressure? An Instagram post claims that magnesium deficiency the leading cause of high blood pressure. However, upon being fact-checked, it is found Misleading. While there are studies indicating magnesium deficiency can contribute to hypertension but is not the primary cause, as multiple factors like genetics, diet, and lifestyle influence it. Doctor experts have refuted this claim and called it Misleading. Thank you Dr. Jinendra K Jain, and Dr Swarup Pal  for providing your expert opinion to fact check this claim. For more information, click on the link below: https://lnkd.in/gM4S2qCh #magnesium #highbloodpressure #magnesiumdeficiency

Abbott India: Resignation of Sridhar Kadangode as CFO, Murari Ranganathan as Commercial Director - Women's Health, Metabolics and International Business Abbott India has announced the resignation of Sridhar Kadangode as Chief Financial Officer of the Company and Murari Ranganathan as Commercial Director - Women’s Health, Metabolics and International Business of the Company, effective close of business hours of February 26, 2025 and February 25, 2025 respectively, to pursue opportunities outside the Company. Medical Dialogues team had earlier reported that Namita Shah - Associate Director - New Product Introduction and Therapy Area Strategy, had tendered her resignation from employment of the Company with effect from the close of business hours of April 15, 2025. #abbottindia #abbottindianews #resignation #sridharkadangode #murariranganathan

Natco Pharma appoints G Vasan as Vice President - (Operations) NATCO Pharma  has announced that G. Vasan has been designated as Vice President - (Operations) of the Company w.e.f. 27th February, 2025. G. Vasan is a Postgraduate in Chemistry and having 35+ years’ experience with the multi-industrial experience in the field of Fine, Speciality chemicals and Pharmaceutical Industries. He is leading NATCO’s Chemical Division - Chennai for the last 12 years as Head - Operations. Prior to NATCO worked as GM-Operations with M/s. Shasun Pharmaceuticals Limited, Cuddalore, GM - Operations with M/s. WANBURY Limited, Tanuku and Chief Manager - Production with M/s. Piramal Enterprises, Chennai and worked in Production for about 12 years with M/s. Sanmar. #natcopharma #natcopharmanews #gvasan #wanbury #piramalenterprises

Can Coconut Oil Pulling Heal Gingivitis or Gum Inflammation? An Instagram post claims that Coconut Oil Pulling can Heal Gingivitis. However, upon being fact-checked, it is found False. While there are studies indicating that coconut oil pulling may help with oral health, there is no scientific evidence that it can heal gingivitis or gum inflammation alone. Dentists have refuted this claim and called it False. For more information, click on the link below: https://lnkd.in/gJ6S8-q9 #coconutoilpulling #oilpulling #gingivitis #guminflammation

World Rare Disease Day: Key Challenges & Developments decoded with Prasanna Shirol, ORDI & Dr Neerja Gupta, AIIMS - Video Rare diseases may be uncommon, but their impact on individuals, families, and communities is profound. Since 2008, Rare Disease Day has been observed globally on February 28 (or February 29 in leap years) to raise awareness among policymakers and the public about rare diseases and their impact on patients' lives. This global campaign highlights the challenges faced by individuals with rare diseases and their families while celebrating their strength, resilience, and courage. Today, we are conducting a panel discussion on rare disease awareness, where esteemed experts will share insights on the challenges, advancements, and policy initiatives needed to support those affected by rare diseases. Join us for an insightful discussion featuring: 🔹 Prasanna Shirol – Rare Disease Advocate, Co-founder & Director, ORDI 🔹 Dr Neerja Gupta  – Additional Professor, Division of Genetics, Department of Pediatrics, AIIMS, New Delhi Following are the questions discussed in the video: 1. What are some of the most significant challenges faced in diagnosing rare diseases? 2. India is a vast country. Amid rare diseases, which ones are relatively more often encountered in India? 3. How can genetic testing, advancements in genomics, and newer diagnostic tools improve the diagnosis and treatment of rare diseases? 4. Are there any recent breakthroughs in the treatment of rare diseases that you’re particularly excited about? 5. How can healthcare systems better support patients with rare diseases and their families? 6. What can be done to raise awareness about rare diseases among the general public and medical professionals? 7. How can patients and caregivers get involved in clinical trials and research for rare diseases? 8. What are the biggest misconceptions about rare diseases that you wish to dispel? 9. How do you see the future of rare disease treatment evolving in the next decade? 10. What support resources are available for patients and families dealing with rare diseases? #WorldRareDiseaseDay #DrNeerjaGupta #PrasannaShirol

Sanofi Sarclisa combo gets Japanese nod for newly diagnosed multiple myeloma  Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ phase 3 study. In Japan, Sarclisa was launched in August 2020 and has been approved for four different treatment regimens (in combination with pomalidomide and dexamethasone, as monotherapy, in combination with carfilzomib and dexamethasone, or in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma). In addition, Sarclisa has front-line approvals in the EU and the US. In the Asia Pacific region, Sarclisa combination regimens were also recently approved by the National Medical Products Administration in China, specifically Sarclisa-VRd in NDMM patients who are not eligible for autologous stem cell transplant, as well as Sarclisa in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with relapsed or refractory MM who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Sarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on the surface of MM cells, making it a target for antibody-based therapeutics such as Sarclisa. In the US, the non-proprietary name for Sarclisa is isatuximab-irfc, with irfc as the suffix designated in accordance with nonproprietary naming of biological products guidance for industry issued by the US Food and Drug Administration. For more information, click on the link below: https://lnkd.in/gevtpeeH #sanofi #sanofinews #sarclisa #bortezomib #lenalidomide #dexamethasone #multiplemyeloma

Healthcare recruitment platform Jobizo raises USD 1.4 million in pre-Series A funding In a bid to transform healthcare recruitment, Jobizo India, a healthcare HR tech startup, has raised USD 1.4 million in pre-Series A funding, led by Alkemi Growth Capital, to expand its operations and strengthen India's healthcare hiring ecosystem. The funding follows a USD 500,000 seed round in 2022, which was led by Aroa Venture Partners, marking significant growth for the company. Expansion Plans and Market Growth Jobizo plans to utilize the fresh capital for product enhancements, expanding its reach to six to eight Indian cities, and tapping into international markets. As per various media accounts, the startup, which operates an AI-powered platform connecting healthcare professionals with employers, has already facilitated over 20,000 jobs and experienced a 500% growth since its seed round. With this funding boost, Jobizo aims to create 100,000 healthcare jobs in India and 3,000 abroad within the next 18 months, contributing to over 10 million additional job hours in healthcare over time. Addressing Hiring Challenges in Healthcare Co-founded by Naveen Trehan and Avishek A., Jobizo is tackling critical hiring challenges in India’s healthcare sector, which has long struggled with staff shortages, high recruitment costs, and time-consuming hiring processes. The platform helps healthcare businesses access a verified talent pool, reducing hiring timelines and operational costs. AI-Powered Platform for Healthcare Talent Jobizo’s AI-driven recruitment solutions allow hospitals and healthcare providers to quickly connect with skilled professionals, ensuring better patient care and optimized workforce management. The startup claims to have already contributed over 10 million additional patient care hours in India, reports Entrackr. As Jobizo expands across key healthcare markets, the fresh capital injection is expected to accelerate its mission of transforming talent acquisition in the healthcare industry, while also boosting employment opportunities for healthcare professionals worldwide. #jobizo #healthcarehrtech #healthcarehiring #aipoweredrecruitment #alkemigrowthcapital #naveentrehan #avishekagarwal #aroraventures

$90,000 Grant for Medical Research: Dive into BFI-BIOME SAMARTH Program with Dr Gaurav Singh, CEO, BFI - Video Medical Dialogues team interacts with Dr Gaurav Singh, Chief Executive Officer, Blockchain for Impact (BFI), a catalyst funder and philanthropic organization advancing the biomedical innovation in India. Dr Gaurav, a visionary has been a pioneering force to make healthcare more affordable and accessible for diverse communities. He shares his insights on the BFI-BIOME Support for Advancement in Medical and Applied Research for Transformative Healthcare (SAMARTH) grant that seeks proposals from clinicians to apply and contribute to impactful solutions that will shape the future of healthcare in our country. Dr Singh shares the vision behind the BFI-BIOME SAMARTH program and how it aligns with the needs of medical research in India. He talks about the specific types of translational biomedical research that his organization are encouraging through the SAMARTH program, and how can clinicians and researchers benefit from this funding. He further describes how the SAMARTH program differs from other available funding avenues in India, particularly for clinical researchers laying emphasis on the key criteria for successful applications, and what steps can medical professionals and faculty take to ensure their proposals stand out. Dr Gaurav highlights how the SAMARTH program specifically addresses the healthcare challenges faced by underserved communities, and how can academic institutions play a role. He elaborates on the role of academic and public-private collaborations in advancing healthcare solutions, and how will SAMARTH facilitate this and lastly shares his advice to professors and clinicians in medical colleges looking to apply for this grant, especially those who may be newer to biomedical research. #DrGauravSingh #BFIBIOME #SAMARTH

Marksans Pharma UK arm gets marketing nod for Ibuprofen, Paracetamol Film-coated Tablets MARKSANS PHARMA U.K. LIMITED has announced that its wholly owned subsidiary in UK RelonchemLimited has received Marketing Authorization for the product Ibuprofen and Paracetamol200 mg/500 mg Film-coated Tablets (Bell's Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets). Medical Dialogues team had earlier reported that the Company's wholly owned subsidiary Relonchem Limited had received Marketing Authorization from UKMHRA for the Fluoxetine 10mg Capsules, Fluoxetine 30mg Capsules and Fluoxetine 60mg Capsules. #marksanspharma #marksanspharmanews #ibuprofen #paracetamol

Cadila Pharma unveils advanced pharmaceutical warehouse Cadila Pharmaceuticals Limited has announced the expansion of its state-of-the-art pharmaceutical warehouse to bolster efficiency, streamlining logistics, and supporting the company’s growing market presence. Spanning approximately 30,000 sq. ft., the newly expanded warehouse is designed to optimize storage and distribution. With a storage capacity of 3,888 pallets in the main warehouse and 75 pallets in a temperature-controlled cold room, it ensures safe storage for sensitive products such as vaccines and insulin. The facility is equipped with advanced Warehouse Management Systems (WMS), a fixed racking system, Very Narrow Aisle (VNA) equipment, and reach trucks. Enhanced Operational Efficiency and Logistics The integration of automation and smart logistics solutions is set to significantly enhance efficiency: WMS implementation reduces human error, ensuring accuracy in inventory management. A G + 8 racking system increases material inward capacity, optimizing space utilization. Automated material handling through VNA and WMS integration accelerates operations, improving productivity. Dedicated inward and outward gates minimize product interchange, ensuring regulatory compliance and operational precision. #cadilapharma #cadilapharmanews